LP.8.1 variant adapted COVID-19 vaccine COMIRNATY is now authorized in Canada for individuals 6 months of age and older. It is expected to be available in Canada in the coming weeks. This season's ...

After a pair of high-profile approvals for sickle cell disease gene therapies in the U.S. last month, Pfizer is ushering in the New Year with a regulatory endorsement for its hemophilia B gene therapy ...

With the approval of ABRYSVO® for adults aged 18+, there is now a way to help protect against RSV in a population that previously did not have vaccination options. KIRKLAND, QC, Oct. 21, 2025 /CNW/ - ...

Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...

Jan 3 (Reuters) - Pfizer (PFE.N), opens new tab said on Wednesday that Canada's health regulator approved its gene therapy for the treatment of a rare inherited bleeding disorder called hemophilia B ...

(RTTNews) - Pfizer Canada ULC and BioNTech SE (BNTX) announced that Health Canada has authorized the LP.8.1 variant adapted COMIRNATY COVID-19 vaccine for individuals aged 6 months and older. The ...